AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJ
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma
- AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily
- Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's
- AbbVie inks $10.9B Apogee buyout to bag eczema prospect Fierce Biotech
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events